Current status of dendritic cell-based tumor vaccination

Cite This

Files in this item

Checksum: MD5:b8451e66a193158f3cd75f275a64fec4

DANNULL, Jens, Thomas CERNY, Daniel K. ACKERMANN, Marcus GRÖTTRUP, 2000. Current status of dendritic cell-based tumor vaccination. In: Onkologie. 23(6), pp. 544-551. ISSN 0378-584X. eISSN 1423-0240. Available under: doi: 10.1159/000055004

@article{Dannull2000Curre-22144, title={Current status of dendritic cell-based tumor vaccination}, year={2000}, doi={10.1159/000055004}, number={6}, volume={23}, issn={0378-584X}, journal={Onkologie}, pages={544--551}, author={Dannull, Jens and Cerny, Thomas and Ackermann, Daniel K. and Gröttrup, Marcus} }

<rdf:RDF xmlns:dcterms="" xmlns:dc="" xmlns:rdf="" xmlns:bibo="" xmlns:dspace="" xmlns:foaf="" xmlns:void="" xmlns:xsd="" > <rdf:Description rdf:about=""> <dcterms:bibliographicCitation>Onkologie ; 23 (2000), 6. - S. 544-551</dcterms:bibliographicCitation> <dspace:isPartOfCollection rdf:resource=""/> <dc:rights>terms-of-use</dc:rights> <dcterms:hasPart rdf:resource=""/> <dcterms:available rdf:datatype="">2013-03-27T07:12:08Z</dcterms:available> <dc:creator>Cerny, Thomas</dc:creator> <dc:creator>Gröttrup, Marcus</dc:creator> <dcterms:isPartOf rdf:resource=""/> <dcterms:title>Current status of dendritic cell-based tumor vaccination</dcterms:title> <dc:creator>Ackermann, Daniel K.</dc:creator> <bibo:uri rdf:resource=""/> <dc:contributor>Dannull, Jens</dc:contributor> <dc:date rdf:datatype="">2013-03-27T07:12:08Z</dc:date> <dc:contributor>Cerny, Thomas</dc:contributor> <dcterms:abstract xml:lang="eng">For several decades, approaches utilizing nonspecific immune stimulants have provided evidence that the immune system, when properly activated, may eradicate cancer cells. However, it was only after the identification of the first human tumor-associated antigen, less than a decade ago, that development of specific vaccination procedures for cancer patients became feasible. Recent insights into the pivotal role of dendritic cells (DCs) for initiation and regulation of immune responses have allowed the design of DC-based tumor vaccination trials. In addition, the development of methods to raise large numbers of DCs from peripheral blood monocytes has paved the way for their clinical application. Tumor-specific vaccination utilizing antigen-loaded autologous DCs, has become practical and applicable to patients and may lead to vigorous antitumor responses. This review outlines recent progress, obstacles still to be overcome, and the future potential of DC-based vaccination.</dcterms:abstract> <dc:language>eng</dc:language> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Dannull, Jens</dc:creator> <dcterms:issued>2000</dcterms:issued> <dspace:hasBitstream rdf:resource=""/> <dc:contributor>Ackermann, Daniel K.</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:contributor>Gröttrup, Marcus</dc:contributor> <dcterms:rights rdf:resource=""/> </rdf:Description> </rdf:RDF>

Downloads since Oct 1, 2014 (Information about access statistics)

Dannull_221442.pdf 50

This item appears in the following Collection(s)

Search KOPS


My Account